In March 2018, Celgene (Nasdaq: CELG) announced its intention to co-develop and co-market bb2121, a bluebird bio (Nasdaq: BLUE) CAR-T cell therapy for relapsed multiple myeloma. In conversation with The Pharma Letter, Tuomo Pätsi, worldwide president for hematology and oncology markets, makes a strong case for the drug.
"We believe bb2121 has the potential to have a significant impact on advancing research around potential new options for these patients," he says.
Shaking off a share-scarring blip
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze